Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Amgen
(NQ:
AMGN
)
311.29
+32.90 (+11.82%)
Official Closing Price
Updated: 4:15 PM EDT, May 3, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Amgen
< Previous
1
2
3
4
5
Next >
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Amgen Inc. (AMGN) on Behalf of Investors
March 15, 2023
From
Law Offices of Howard G. Smith
Via
Business Wire
AMGEN INC. (NASDAQ: AMGN) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Announces that a Securities Class Action Lawsuit Has Been Filed Against Amgen Inc. (NASDAQ: AMGN)
March 15, 2023
From
Bernstein Liebhard LLP
Via
GlobeNewswire
SHAREHOLDER ACTION REMINDER: The Schall Law Firm Encourages Investors in Amgen Inc. with Losses of $100,000 to Contact the Firm
March 15, 2023
From
The Schall Law Firm
Via
Business Wire
AMGEN ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Amgen Inc. and Encourages Investors to Contact the Firm
March 14, 2023
From
Bragar Eagel & Squire, P.C.
Via
Business Wire
The Law Offices of Frank R. Cruz Announces Investigation of Amgen Inc. (AMGN) on Behalf of Investors
March 14, 2023
From
The Law Offices of Frank R. Cruz
Via
Business Wire
SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Amgen Inc. with Losses of $100,000 to Contact the Firm
March 14, 2023
From
The Schall Law Firm
Via
Business Wire
Shareholder Alert: Robbins LLP Informs Investors of Class Action Against Amgen Inc. (AMGN)
March 14, 2023
From
Robbins LLP
Via
Business Wire
Monoclonal Antibodies? Avid Bioservices surges 32% on Blowout Q3
March 14, 2023
Avid Bioservices Inc. (NASDAQ: CDMO) is a contract development and manufacturing organization (CDMO) that specializes in producing monoclonal antibodies,
Via
MarketBeat
Exposures
COVID-19
AMGN EQUITY ALERT: ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Amgen Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – AMGN
March 14, 2023
From
The Rosen Law Firm, P.A.
Via
Business Wire
AMGN INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Files Class Action Lawsuit Against Amgen Inc. and Announces Opportunity for Investors with Substantial Losses to Lead Case
March 13, 2023
From
Robbins Geller Rudman & Dowd LLP
Via
Business Wire
Is Amazon a Blue Chip Stock?
February 28, 2023
Is Amazon a blue chip stock or does it fit into a different category? Learn more about Amazon.com Inc. and how to categorize it with MarketBeat.
Via
MarketBeat
Is Biotech Immunocore About To Make A 25% Price Move?
February 07, 2023
Small-cap Immunocore has been a price leader within the biotech industry. Analysts have a "buy" rating on the stock and estimate that it will move 25% higher.
Via
MarketBeat
Topics
ETFs
Harpoon Therapeutics Remains Volatile After Promising News
December 14, 2022
Harpoon Therapeutics offers an example of biotech's volatility. The stock advanced as much as 191% intraday Monday before settling down to a gain of 22.61%.
Via
MarketBeat
Biotech Sector Witnessing Growing Revenue Potential in Ongoing Battle Against Pancreatic Cancer
November 15, 2022
FN Media Group Presents USA News Group News Commentary Vancouver, BC –November 15, 2022 – USA News Group – Roughly five years after selling its flagship cancer asset Onivyde from to French biotech...
Via
FinancialNewsMedia
Topics
Death
Exposures
Death
Is Mid-Cap Neurocrine Biosciences A Buy After Blowout Q3 Report?
November 11, 2022
Neurocrine Biosciences trended higher with the broad market Thursday, coming within a penny of Tuesday’s high of $125.99. It is forming a bullish channel.
Via
MarketBeat
This Company Is Racing Toward Providing Comfort And Safety To Millions Of Psoriasis Sufferers
October 31, 2022
The competition between pharmaceutical company trials to help the 2% to 3% of the population suffering from chronic psoriasis is heating up.
Via
TheNewswire.com
Exposures
Product Safety
Merck Nears Breakout Point After October Surprise Good News
October 19, 2022
Dow component Merck is within 2% of an all-time high after rallying 7.30% in the past month. It got a boost from news about two new treatments.
Via
MarketBeat
Topics
Stocks
Exposures
US Equities
MarketBeat: Week in Review 10/10-10/14
October 15, 2022
A volatile week is ending with the market moving lower. Here are some of the stories the MarketBeat analysts were covering this week.
Via
MarketBeat
Exposures
COVID-19
Amgen Shares Leap Higher On Upbeat Outlook For Obesity Treatment
October 13, 2022
Shares of Amgen soared 5.72% Tuesday and added to those gains Wednesday. The gap-up followed a Morgan Stanley upgrade and increase to the price target.
Via
MarketBeat
Two Appealing Biotech Stocks for Two Distinct investors
August 08, 2022
Investing in biotech stocks carries both risk and reward. This article highlights two biotech companies that may appeal to specific investing styles
Via
MarketBeat
Topics
Intellectual Property
Exposures
COVID-19
Intellectual Property
ChemoCentryx (NASDAQ: CCXI) to be Acquired by Amgen (NASDAQ: AMGN) for $3.7 Billion in Cash
August 04, 2022
ChemoCentryx, Inc. (NASDAQ: CCXI) is engaged as a biopharmaceutical company that is focused on the research, development and commercialization of
Via
Spotlight Growth
Should You Buy AbbVie Ahead Of Earnings?
July 28, 2022
AbbVie (NYSE: ABBV) is due to announce its earnings over the next couple of days. Some investors are considering buying it in advance, but it is worth the investment?
Via
MarketBeat
Amgen Inc. (NASDAQ:AMGN) Investor Alert: Investigation over Potential Wrongdoing
July 07, 2022
San Diego, CA -- (SBWIRE) -- 07/07/2022 -- An investigation was announced over potential breaches of fiduciary duties by certain officers and directors at Amgen Inc.
Via
SBWire
Rising Cases Of Mental Health Disorders of Stress, Anxiety & Addiction Fueling Need for Central Nervous System Therapeutics
June 07, 2022
Palm Beach, FL – June 7, 2022 – FinancialNewsMedia.com News Commentary – The global Central Nervous System (CNS) treatments and its market revenues had been steadily growing pre-pandemic and are still...
Via
FinancialNewsMedia
Exposures
COVID-19
NASDAQ: AMGN Investor Notice: Investigation over Possible Securities Laws Violations by Amgen Inc.
May 11, 2022
San Diego, CA -- (SBWIRE) -- 05/11/2022 -- An investigation was announced for investors of Amgen Inc. (NASDAQ: AMGN) shares over potential securities laws violations by Amgen Inc.
Via
SBWire
Ongoing Investigation Reminder: The Schall Law Firm Encourages Investors in Amgen Inc. with Losses of $100,000 to Contact the Firm
May 04, 2022
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Ongoing Investigation Reminder: The Schall Law Firm Encourages Investors in Amgen Inc. with Losses of $100,000 to Contact the Firm
May 03, 2022
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Ongoing Investigation Alert: The Schall Law Firm Encourages Investors in Amgen Inc. with Losses of $100,000 to Contact the Firm
May 03, 2022
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
INVESTIGATION NOTICE: The Schall Law Firm Encourages Investors in Amgen Inc. with Losses of $100,000 to Contact the Firm
May 02, 2022
From
The Schall Law Firm
Via
Business Wire
INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in Amgen Inc. with Losses of $100,000 to Contact the Firm
April 29, 2022
From
The Schall Law Firm
Via
Business Wire
< Previous
1
2
3
4
5
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.